US Patent

US12059497 — Stabilizing camptothecin pharmaceutical compositions

Formulation · Assigned to Ipsen Biopharm Ltd · Expires 2036-10-15 · 10y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a formulation of irinotecan (Camptosar) in the form of phospholipid liposomes with improved storage stability.

USPTO Abstract

Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

Drugs covered by this patent

Camptosar (Irinotecan Hydrochloride) · Pfizer

Patent Metadata

Patent number: US12059497
Jurisdiction: US
Classification: Formulation
Expires: 2036-10-15
Drug substance claim: No
Drug product claim: Yes
Assignee: Ipsen Biopharm Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.